SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Quek ML, Stein JP, Clark PE, et al. Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer. 2003; 98: 955961.
  • 2
    Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003; 361: 19271934.
  • 3
    [No authors listed]. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet. 1999; 354: 533540.
  • 4
    Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349: 859866.
  • 5
    Bono AV, Benvenuti C, Reali L, et al. Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group. Prog Clin Biol Res. 1989; 303: 533540.
  • 6
    Stockle M, Meyenburg W, Wellek S, et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol. 1992; 148: 302306.
  • 7
    Skinner DG, Daniels JR, Russell CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 1991; 145: 459464.
  • 8
    Studer UE, Bacchi M, Biedermann C, et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol. 1994; 152: 8184.
  • 9
    Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol. 1996; 155: 495499.
  • 10
    Bladder cancer including upper tract tumors and urothelial carcinoma of the prostate. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology 2006, version 1. Online monograph. Available at URL: http://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf Accessed March 18, 2006.
  • 11
    McKiernan JM, Decastro GJ, Gilbert S, et al. Factors associated with perioperative systemic chemotherapy for bladder cancer: a population based study [Abstract 4701]. 2005 ASCO Annual Meeting.
  • 12
    Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003; 23: 460464.
  • 13
    Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J Urol. 2005; 174: 1420.
  • 14
    Small EJ, Halabi S, Dalbagni G, et al. Overview of bladder cancer trials in the cancer and leukemia group B. Cancer. 2003; 97(8 Suppl ): 20902098.
  • 15
    National Cancer Institute. Phase III randomized study of cisplatin and gemcitabine with or without paclitaxel in patients with stage IV transitional cell carcinoma of the urothelium. Available at URL: http://www.cancer.gov/clinicaltrials/EORTC-30987#EntryCriteria_CDR0000068793 Accessed March 18, 2006.
  • 16
    National Cancer Institute. Phase III randomized study of adjuvant doxorubicin and gemcitabine followed by paclitaxel and cisplatin versus adjuvant cisplatin and gemcitabine in patients with completely resected locally advanced transitional cell carcinoma of the bladder. Available at URL: http://www.cancer.gov/clinicaltrials/CALGB-90104#EntryCriteria_CDR0000068554 Accessed March 18, 2006.
  • 17
    Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130: 461470.
  • 18
    K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1 ): S1266.
  • 19
    Cockroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 3141.
  • 20
    Jelliffe RW. Estimation of creatinine clearance when urine cannot be collected. Lancet. 1971; 1: 975976.
  • 21
    Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003; 41: 112.
  • 22
    Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001; 19: 26382646.
  • 23
    Murray PT, Ratain MJ. Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs. J Clin Oncol. 2003; 21: 26332635.
  • 24
    Sonpavde G, Petrylak DP. Perioperative chemotherapy for bladder cancer. Crit Rev Oncol Hematol. 2006; 57: 133144.
  • 25
    Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005; 55: 1030.
  • 26
    Farnham SB, Cookson MS, Alberts G, Smith JAJr., Chang SS. Benefit of radical cystectomy in the elderly patient with significant co-morbidities. Urol Oncol. 2004; 22: 178181.
  • 27
    Hollenbeck BK, Miller DC, Taub D, et al. Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old or older. Urology. 2004; 64: 292297.
  • 28
    Clark PE, Stein JP, Groshen SG, et al. Radical cystectomy in the elderly: Comparison of survival between younger and older patients. Cancer. 2005; 103: 546552.
  • 29
    Guidance for industry: pharmacokinetics in patients with impaired renal function—study design, data analysis, and impact on dosing and labeling. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration: Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), 1998.
  • 30
    Wright JG, Boddy AV, Highley M, Fenwick J, McGill A, Calvert AH. Estimation of glomerular filtration rate in cancer patients. Br J Cancer. 2001; 84: 452459.
  • 31
    Calvert AH, Boddy A, Bailey NP, et al. Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. Semin Oncol. 1995; 22: 9198.
  • 32
    Studer UE, Varol C, Danuser H. Orthotopic ileal neobladder. BJU Int. 2004; 93: 183193.
  • 33
    Rinnab L, Straub M, Hautmann RE, Braendle E. Postoperative resorptive and excretory capacity of the ileal neobladder. BJU Int. 2005; 95: 12891292.
  • 34
    Galsky MD, Mironov S, Scattergood J, et al. Phase I/II study of dose-dense sequential chemotherapy in renal impaired patients (pts) with transitional cell carcinoma (TCC) of the urothelium [Abstract 4529]. 2005 ASCO Annual Meeting.
  • 35
    Hussain M, Vaishampayan U, Du W, Redman B, Smith DC. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol. 2001; 19: 25272533.
  • 36
    Smith DC, Bhandari M, Hussain M, et al. Paclitaxel, carboplatin and gemcitabine (PCG) as neoadjuvant therapy in patients with locally advanced transitional cell carcinoma (TCC) of the bladder [Abstract 4541]. 2004 ASCO Annual Meeting.